Scarica l'app Stockscreener
162.79
0.96%
1.6201
Precedente Chiudi:
$161.17
Aprire:
$161.86
Volume 24 ore:
162.40K
Relative Volume:
0.15
Capitalizzazione di mercato:
$12.57B
Reddito:
$8.27B
Utile/perdita netta:
$173.28M
Rapporto P/E:
74.98
EPS:
2.1712
Flusso di cassa netto:
$785.90M
1 W Prestazione:
-0.52%
1M Prestazione:
-3.56%
6M Prestazione:
+8.05%
1 anno Prestazione:
+3.08%
Intervallo 1D:
$160.46
$164.65
Intervallo di 1 settimana:
$150.85
$167.51
Portata 52W:
$66.57
$203.91
Icon Plc Stock (ICLR) Company Profile
Nome
Icon Plc
Settore
Industria
Telefono
-
Indirizzo
-
Compare ICLR vs TMO, DHR, IDXX, NTRA, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
162.99 | 13.02B | 8.27B | 173.28M | 785.90M | 2.1712 |
TMO
Thermo Fisher Scientific Inc
|
587.13 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.72 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
587.76 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
317.63 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
145.09 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2026-02-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2026-02-18 | Aggiornamento | TD Cowen | Hold → Buy |
| 2026-02-17 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2026-02-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2026-02-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-01-08 | Downgrade | Truist | Buy → Hold |
| 2025-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-11-13 | Iniziato | BMO Capital Markets | Market Perform |
| 2025-09-09 | Downgrade | Jefferies | Buy → Hold |
| 2025-09-03 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-08-21 | Downgrade | Citigroup | Buy → Neutral |
| 2025-07-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Downgrade | TD Cowen | Buy → Hold |
| 2025-04-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Iniziato | Redburn Atlantic | Neutral |
| 2024-09-18 | Iniziato | Leerink Partners | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2023-12-15 | Iniziato | Truist | Buy |
| 2023-09-13 | Iniziato | TD Cowen | Outperform |
| 2023-01-17 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-09-07 | Iniziato | UBS | Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-05-24 | Iniziato | Guggenheim | Buy |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-14 | Iniziato | Citigroup | Neutral |
| 2021-04-13 | Ripresa | BofA Securities | Neutral |
| 2021-04-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Iniziato | Barclays | Equal Weight |
| 2021-03-01 | Aggiornamento | UBS | Neutral → Buy |
| 2021-02-26 | Aggiornamento | Truist | Hold → Buy |
| 2020-07-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Hold |
| 2020-01-27 | Downgrade | SunTrust | Buy → Hold |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-09-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Aggiornamento | UBS | Sell → Neutral |
| 2019-01-25 | Aggiornamento | Mizuho | Neutral → Buy |
| 2018-10-26 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Iniziato | UBS | Sell |
| 2018-04-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Reiterato | Mizuho | Neutral |
| 2018-01-19 | Iniziato | Evercore ISI | Outperform |
| 2017-10-27 | Reiterato | Barclays | Equal Weight |
| 2017-09-11 | Iniziato | BofA/Merrill | Buy |
| 2017-07-31 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-07-27 | Reiterato | Mizuho | Neutral |
| 2017-06-29 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Icon Plc Borsa (ICLR) Ultime notizie
ICLR Looks 20.5% Undervalued on GF Value™ - GuruFocus
ICON plc stock rises on Anthropic deal (ICLR:NASDAQ) - Seeking Alpha
ICON plc Announces Multi-Year Collaboration With Anthropic To Bring Frontier AI To Clinical Trials - marketscreener.com
ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials - Business Wire
ICON PLC expected to post earnings of $2.51 a shareEarnings Preview - TradingView
ICON PLC (ICLR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ICON PLC (ICLR) Cash Flow - TradingKey
ICON PLC (ICLR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Icon Plc (ICLRN) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Icon Plc (ICLRN) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
What Just Happened at ICON (ICLR) and Why Did Shares Soar - Kavout | AI
ICON PLC (ICLR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ICLR|ICON PLC|Price:170.260|Chg%:+2.980 - TradingKey
ICLR|ICON PLC|Price:168.602|Chg%:+2.842 - TradingKey
ICON PLC (ICLR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Hybrid Clinical Research Job at ICON plc | Apply Online Now! - BioTecNika
ICON PLC (ICLR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ICLR: Icon Plc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Earnings Preview: Icon PLC to Report Financial Results Post-market on July 29 - 富途牛牛
Icon Plc (ICLRN) Earnings Dates, Call Summary & Reports - TipRanks
ICON Plc Shows Signs of Recovery Amid Industry HeadwindsROE Trend Analysis - dars.gov.et
Icon PLC (ICLR) Up 5.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
ICON Plc (ICLR) is Strengthening After Challenges - Yahoo Finance
ICON Schedules Second Quarter 2026 Earnings Conference Call - BioSpace
ICON Schedules Second Quarter 2026 Earnings C - Moomoo
ICON plc to announce Q2FY26 results on July 29 - scanx.trade
ICON plc (NASDAQ: ICLR) schedules Q2 2026 earnings results call - Stock Titan
Press Release: ICON Schedules Second Quarter 2026 Earnings Conference Call - Moomoo
Icon defends claim it left investors with ‘billions in losses’ - The Times
ICON plc Q1 2026 Earnings: EPS Beat Lifts Results, Yet Stock Declines 1.21%Earnings Call Q&A - dars.gov.et
ICON PLC : Leerink Partners Raises Target Pri - Moomoo
Earnings Preview: Icon PLC (ICLR) Q2 Earnings Expected to Decline - Yahoo Finance
Global Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate Growth - GlobeNewswire Inc.
ICON Plc (ICLR) Stock Analysis: A Healthcare Giant With 7.81% Potential Upside - DirectorsTalk Interviews
ETFs Investing in ICON Plc Stocks - TradingView
Icon reiterates 2026 guidance of $7.85B-$8.15B revenue and $10-$11 EPS amid 1.42x net book-to-bill - MSN
Prosight Management, LP's Icon PLC(ICLR) Holding History - GuruFocus
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in ICON plc (ICLR) to Contact Law Firm - mydailyrecord.com
ICON plc shares drop after internal probe into accounting practices announced - Pluang
ICON plc (ICLR) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
RBC Capital Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $185 - 富途牛牛
ICON Stock and the CRO Trends Shaping Its Next Growth Phase - The Globe and Mail
ICON plc highlights its position in global clinical research. The Nasdaq-listed group continues to b - Ad-hoc-news.de
ICON Public Limited Company (ICLR) Fell Due to Uncertainty Surrounding Reported Earnings - Yahoo Finance
ICON plc outlines its role in global clinical research as a Nasdaq-listed CRO - ad-hoc-news.de
Is ICLR Stock a Value Trap or Turnaround After an Earnings Reset? - TradingView
ICON Stock Outlook 2026 as Margin Woes Meet a Stronger Backlog Base - TradingView
Icon PLC | 3: Initial statement of beneficial ownership of securities- O'Neill Julie - Moomoo
ICON shares rise as earnings beat and CEO flags strong booking momentum - MSN
ICLRIcon Plc Options - Finviz
ICON plc. Shares trade on Nasdaq amid steady business backdrop. - AD HOC NEWS
Icon Plc Azioni (ICLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):